$695 | Single User
$1395 | Global License

Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 05 May 2014 | 120 | In Stock

Introduction

Scope



The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in part by a handful of products (Avonex, Betaseron, Copaxone and Rebif) that are both effective, very well established and which deliver broadly comparable efficacy. In more recent years, an 'oral revolution' has advanced the therapeutic optionality for MS patients, but simultaneously left room for further improvements.


As patients await the next generation of therapies to emerge from the clinic – potentially improving care in certain subtypes of the disease or facilitating the repair of damage caused by MS – another dynamic is likely to emerge via the potential launch of generic Copaxone products.


Despite the competitive nature of this disease market, prices for MS drugs have risen notably in recent years; a recently published (by Bloomberg) list of 73 drugs that have seen a US list price increase of 75 percent or more since 2007 included five of the most widely prescribed MS drugs.


With the potential launch of generic Copaxone set to provide some form of platform for pricing pressure, will other factors that have driven brand loyalty in MS be overlooked or will the dynamics that have allowed this therapy to persist as one the strongest growing in recent years remain in place?


Puchase Reasons


Against this backdrop, FirstWord polled 186 neurologists based in the US and EU5 to ask them a series of questions about their approach to using MS therapies. Specifically we asked them...


  • How they rate their personal level of loyalty to the MS treatments they prescribe?

  • In what segment of the MS market is their loyalty to particular products strongest?

  • What a new therapy would need to demonstrate versus existing treatments to change their prescribing habits?

  • What clinical attribute (apart from efficacy) they believe is the most important differentiator between approved MS therapies?

  • What commercial attribute they believe is the most important differentiator between approved MS therapies?
  • Table of Contents
    for Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    120 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...